Published in J Virol on February 01, 1987
Distinct types of lung disease caused by functional subsets of antiviral T cells. J Exp Med (1994) 2.99
Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J Virol (1987) 2.41
Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med (1997) 2.40
Synthesis of the membrane fusion and hemagglutinin proteins of measles virus, using a novel baculovirus vector containing the beta-galactosidase gene. J Virol (1990) 2.17
Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol (1991) 2.05
Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc Natl Acad Sci U S A (2001) 2.04
Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J Virol (1988) 1.91
Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J Virol (1999) 1.71
Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol (1988) 1.60
Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol (2001) 1.58
The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection. J Virol (1990) 1.57
Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus. J Virol (1992) 1.51
Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J Exp Med (1998) 1.48
Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. J Virol (1997) 1.48
Recombinant vaccinia viruses carrying the N gene of human respiratory syncytial virus: studies of gene expression in cell culture and immune response in mice. J Virol (1987) 1.38
Induction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent. J Virol (1999) 1.25
Vaccinia virus recombinants expressing either the measles virus fusion or hemagglutinin glycoprotein protect dogs against canine distemper virus challenge. J Virol (1991) 1.24
N-glycans of F protein differentially affect fusion activity of human respiratory syncytial virus. J Virol (2001) 1.21
Respiratory syncytial virus infection in C57BL/6 mice: clearance of virus from the lungs with virus-specific cytotoxic T cells. J Virol (1991) 1.20
Newcastle disease virus fusion protein expressed in a fowlpox virus recombinant confers protection in chickens. J Virol (1990) 1.11
Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge. J Virol (1988) 1.10
Infectivity of a human respiratory syncytial virus lacking the SH, G, and F proteins is efficiently mediated by the vesicular stomatitis virus G protein. J Virol (2003) 1.05
Virally delivered cytokines alter the immune response to future lung infections. J Virol (2007) 1.01
Synthesis, cellular location, and immunogenicity of bovine herpesvirus 1 glycoproteins gI and gIII expressed by recombinant vaccinia virus. J Virol (1989) 1.00
Respiratory syncytial virus limits alpha subunit of eukaryotic translation initiation factor 2 (eIF2alpha) phosphorylation to maintain translation and viral replication. J Biol Chem (2010) 0.95
Influence of respiratory syncytial virus strain differences on pathogenesis and immunity. Curr Top Microbiol Immunol (2013) 0.93
Vaccinia virus vectors: new strategies for producing recombinant vaccines. Clin Microbiol Rev (1990) 0.92
Molecular dissection of cis-acting regulatory elements from 5'-proximal regions of a vaccinia virus late gene cluster. J Virol (1988) 0.90
RSV fusion (F) protein DNA vaccine provides partial protection against viral infection. Virus Res (2009) 0.89
Bovine respiratory syncytial virus protects cotton rats against human respiratory syncytial virus infection. J Virol (1993) 0.84
Role of individual glycoproteins of human parainfluenza virus type 3 in the induction of a protective immune response. J Virol (1988) 0.84
Protection of mice from respiratory Sendai virus infections by recombinant vaccinia viruses. J Virol (1997) 0.83
Current approaches to vaccine preparation. Can Vet J (1990) 0.79
A novel influenza virus hemagglutinin-respiratory syncytial virus (RSV) fusion protein subunit vaccine against influenza and RSV. J Virol (2013) 0.75
Targeting vaccinia virus-expressed secretory beta subunit of human chorionic gonadotropin to the cell surface induces antibodies. Infect Immun (1995) 0.75
Sequencing end-labeled DNA with base-specific chemical cleavages. Methods Enzymol (1980) 287.68
General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol (1984) 10.98
Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol (1969) 10.85
Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis (1985) 5.91
Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1985) 5.42
Two distinct subtypes of human respiratory syncytial virus. J Gen Virol (1985) 5.19
The role of viral glycoproteins in adsorption, penetration, and pathogenicity of viruses. Rev Infect Dis (1980) 4.61
Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein. J Virol (1983) 4.05
Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein. Proc Natl Acad Sci U S A (1985) 3.93
Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol (1986) 3.64
Nucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus. Proc Natl Acad Sci U S A (1984) 3.42
Importance of antibodies to the fusion glycoprotein of paramyxoviruses in the prevention of spread of infection. J Exp Med (1980) 3.32
Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology (1984) 3.27
cDNA cloning and transcriptional mapping of nine polyadenylylated RNAs encoded by the genome of human respiratory syncytial virus. Proc Natl Acad Sci U S A (1983) 3.05
Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun (1984) 2.86
Fusion protein of the paramyxovirus simian virus 5: nucleotide sequence of mRNA predicts a highly hydrophobic glycoprotein. Proc Natl Acad Sci U S A (1984) 2.82
Identification of a tenth mRNA of respiratory syncytial virus and assignment of polypeptides to the 10 viral genes. J Virol (1984) 2.45
Respiratory syncytial virus envelope glycoprotein (G) has a novel structure. Nucleic Acids Res (1985) 2.37
Purification and characterization of GP90, one of the envelope glycoproteins of respiratory syncytial virus. J Gen Virol (1984) 2.30
Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge. J Virol (1986) 2.18
Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J Infect Dis (1982) 2.17
Fusion glycoprotein of human parainfluenza virus type 3: nucleotide sequence of the gene, direct identification of the cleavage-activation site, and comparison with other paramyxoviruses. Virology (1986) 2.14
Respiratory syncytial virus infection in mice. Infect Immun (1984) 2.14
The genome of respiratory syncytial virus is a negative-stranded RNA that codes for at least seven mRNA species. J Virol (1982) 2.01
Expression of the major glycoprotein G of human respiratory syncytial virus from recombinant vaccinia virus vectors. Proc Natl Acad Sci U S A (1986) 1.85
Respiratory syncytial virus fusion glycoprotein: nucleotide sequence of mRNA, identification of cleavage activation site and amino acid sequence of N-terminus of F1 subunit. Nucleic Acids Res (1985) 1.69
Respiratory syncytial virus polypeptides. III. The envelope-associated proteins. J Gen Virol (1983) 1.65
Respiratory syncytial virus infection in inbred mice. Infect Immun (1979) 1.60
Control of expression of the vaccinia virus thymidine kinase gene. J Virol (1981) 1.60
Attempts to demonstrate hemagglutination and hemadsorption by respiratory syncytial virus. Appl Microbiol (1971) 1.29
Human antibody-dependent cell-mediated cytotoxicity against target cells infected with respiratory syncytial virus. Clin Exp Immunol (1977) 1.18
Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science (1999) 36.25
2.2 Mb of contiguous nucleotide sequence from chromosome III of C. elegans. Nature (1994) 21.30
The Problem of Infection as Presented by Bacterial Invasion of the Chorio-Allantoic Membrane of Chick Embryos. Am J Pathol (1937) 18.62
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Virus Infection of Human Fetal Membranes Grafted on the Chorioallantois of Chick Embryos. Am J Pathol (1942) 14.65
Infection of Newborn Syrian Hamsters with the Virus of Mare Abortion (Dimock and Edwards). Am J Pathol (1942) 13.70
Order of transcription of genes of vesicular stomatitis virus. Proc Natl Acad Sci U S A (1976) 7.61
Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med (1990) 7.00
Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci U S A (1995) 6.95
Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science (1998) 6.79
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Infectious defective interfering particles of VSV from transcripts of a cDNA clone. Cell (1992) 5.72
Dual Virus Infection of Single Cells. Am J Pathol (1942) 5.66
Anti-cell antibody in macaques. Nature (1991) 5.56
New antigen-antibody system in Australia-antigen-positive hepatitis. Lancet (1971) 5.41
Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst (2000) 4.39
Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein. Proc Natl Acad Sci U S A (1985) 3.93
Replication and amplification of defective interfering particle RNAs of vesicular stomatitis virus in cells expressing viral proteins from vectors containing cloned cDNAs. J Virol (1990) 3.93
THE CULTIVATION FROM GRANULOMA INGUINALE OF A MICROORGANISM HAVING THE CHARACTERISTICS OF DONOVAN BODIES IN THE YOLK SAC OF CHICK EMBRYOS. Science (1943) 3.61
Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. J Clin Oncol (1991) 3.50
Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet (1995) 3.47
Nucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus. Proc Natl Acad Sci U S A (1984) 3.42
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology (1984) 3.27
DNA-bound Fos proteins activate transcription in yeast. Cell (1988) 3.22
Actin filament organization in the fish keratocyte lamellipodium. J Cell Biol (1995) 3.20
Failure of a single-headed kinesin to track parallel to microtubule protofilaments. Nature (1995) 3.16
Extent of terminal complementarity modulates the balance between transcription and replication of vesicular stomatitis virus RNA. Proc Natl Acad Sci U S A (1994) 3.13
Pathogenesis of herpes simplex virus infection in chick embryos. Am J Pathol (1940) 3.12
cDNA cloning and transcriptional mapping of nine polyadenylylated RNAs encoded by the genome of human respiratory syncytial virus. Proc Natl Acad Sci U S A (1983) 3.05
N protein alone satisfies the requirement for protein synthesis during RNA replication of vesicular stomatitis virus. J Virol (1984) 3.00
Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control (2000) 2.85
Influenza, respiratory syncytial virus, and pneumonia in Glasgow, 1962-5. Br Med J (1967) 2.76
Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. J Clin Microbiol (1999) 2.68
Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature (1990) 2.65
Comparison of baseline and repeated measure covariate techniques in the Framingham Heart Study. Stat Med (1988) 2.62
RNA synthesis by vesicular stomatitis virus and a small plaque mutant: effects of cycloheximide. J Virol (1973) 2.58
The product of the respiratory syncytial virus M2 gene ORF1 enhances readthrough of intergenic junctions during viral transcription. J Virol (1998) 2.56
Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us? Am J Transplant (2006) 2.53
Identification of a tenth mRNA of respiratory syncytial virus and assignment of polypeptides to the 10 viral genes. J Virol (1984) 2.45
Mapping and identification of the vaccinia virus thymidine kinase gene. J Virol (1982) 2.44
Transcription and replication of nonsegmented negative-strand RNA viruses. Curr Top Microbiol Immunol (2004) 2.41
Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J Virol (1987) 2.41
Permanent, direct His-bundle pacing: a novel approach to cardiac pacing in patients with normal His-Purkinje activation. Circulation (2000) 2.38
Fine structure analysis and nucleotide sequence of the vaccinia virus thymidine kinase gene. Proc Natl Acad Sci U S A (1983) 2.35
Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature (1997) 2.31
Respiratory syncytial virus. Brief review. Arch Virol (1985) 2.31
Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus. Proc Natl Acad Sci U S A (1998) 2.31
Incidence and prevalence of diabetes in Manitoba, 1986-1991. Diabetes Care (1996) 2.30
Inhibition of protein synthesis in L cells infected with vesicular stomatitis virus. J Virol (1972) 2.29
Synthesis of vesicular stomatitis virus negative-strand RNA in vitro: dependence on viral protein synthesis. J Virol (1982) 2.28
Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J Virol (1998) 2.21
Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge. J Virol (1986) 2.18
Primary amoebic meningoencephalitis. Lancet (1972) 2.17
The envelope-associated 22K protein of human respiratory syncytial virus: nucleotide sequence of the mRNA and a related polytranscript. J Virol (1985) 2.15
Genetic diversity of the attachment protein of subgroup B respiratory syncytial viruses. J Virol (1991) 2.14
THE ENCEPHALITOGENIC PROPERTY OF HERPES VIRUS. Science (1939) 2.14
Respiratory syncytial virus infection in mice. Infect Immun (1984) 2.14
Some improved techniques for the study of rhinoviruses using HeLa cells. Arch Gesamte Virusforsch (1968) 2.13
Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants. J Immunol (1986) 2.13
Comparison of the flutter device to standard chest physiotherapy in hospitalized patients with cystic fibrosis: a pilot study. Chest (1998) 2.12
cis-Acting signals involved in termination of vesicular stomatitis virus mRNA synthesis include the conserved AUAC and the U7 signal for polyadenylation. J Virol (1997) 2.10
Statistical methods in epidemiology: a comparison of statistical methods to analyze dose-response and trend analysis in epidemiologic studies. J Clin Epidemiol (1998) 2.09
The termini of VSV DI particle RNAs are sufficient to signal RNA encapsidation, replication, and budding to generate infectious particles. Virology (1995) 2.06
Cells that express all five proteins of vesicular stomatitis virus from cloned cDNAs support replication, assembly, and budding of defective interfering particles. Proc Natl Acad Sci U S A (1991) 2.05
Benzene and multiple myeloma: appraisal of the scientific evidence. Blood (1999) 2.05
Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells. Immunology (1987) 2.02
The genome of respiratory syncytial virus is a negative-stranded RNA that codes for at least seven mRNA species. J Virol (1982) 2.01
Vesicular stomatitis virus N and NS proteins form multiple complexes. J Virol (1986) 2.01
Mechanism of interferon action: inhibition of viral messenger ribonucleic acid translation in L-cell extracts. J Virol (1972) 2.00
Role of the intergenic dinucleotide in vesicular stomatitis virus RNA transcription. J Virol (1997) 1.99
Awkward moments in patient-physician communication about HIV risk. Ann Intern Med (1998) 1.96
The detection of respiratory syncytial virus in nasopharyngeal aspirates: assessment, formulation, and evaluation of monoclonal antibodies as a diagnostic reagent. J Med Virol (1986) 1.93
Transcriptional map for Newcastle disease virus. J Virol (1980) 1.90
Rhinoviruses. Annu Rev Microbiol (1972) 1.90
Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus. J Virol (1999) 1.89
Increased sensitivity of cell-free protein synthesis to double-stranded RNA after interferon treatment. Nature (1974) 1.86
Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol (1994) 1.86
Expression of the major glycoprotein G of human respiratory syncytial virus from recombinant vaccinia virus vectors. Proc Natl Acad Sci U S A (1986) 1.85
Physiological and DNA characterization of Candida maltosa, a hydrocarbon-utilizing yeast. Arch Microbiol (1975) 1.83
Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation (1999) 1.83
Characterization of the 10 proteins of human respiratory syncytial virus: identification of a fourth envelope-associated protein. Virus Res (1985) 1.82
Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen. J Gen Virol (1987) 1.82
CD4+ lymphocyte function with early human immunodeficiency virus infection. Proc Natl Acad Sci U S A (1989) 1.78